← All trials
NCT04690283
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2021
- Primary completion
- Jul 1, 2022
- Completion date
- Oct 1, 2022
- First posted
- Dec 30, 2020
- Last posted
- Dec 30, 2020
- Enrollment
- 360
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Nanjing NingQi Medicine Science and Technology Co., Ltd.Lead sponsor
- Nanjing Medical UniversityCollaborator
- Nanjing UniversityCollaborator
- Fudan UniversityCollaborator
- Jiangsu Cancer Institute & HospitalCollaborator
- Nanjing Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.